“…However, due to the arising of multidrug resistant (MDR) TB it is required the development of new therapeutic agents, with a unique mechanism of action, able to treat MDR forms of the disease [26]. Several studies have been described, concerning synthesis and biological activity of a large amount of quinoxalines and 1,4-di-Noxide quinoxaline derivatives, where compounds such as 7-chloro-3-(p-substituted)-phenylaminoquinoxaline-2-carbonitrile-1,4-di-N-oxide, 6,7-dichloro-2-ethoxycarbonyl-3-methylquinoxaline-1,4-di-N-oxide and 3-acetamide-6,7-dichloroquinoxaline-2-carbonitrile-1,4-di-N-oxide derivatives have been shown to possess M. tuberculosis growth inhibition values from 99 to 100% [21,27].…”